Physician profile
Jamie A Cannon
NPI 1568514644
$703,887.93
in general payments reported to CMS, 2019-2025
25 companies · $73K in 2025
The $73K reported for 2025 was more than what 99% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112K · 2020: $94K · 2021: $141K · 2022: $118K · 2023: $115K · 2024: $51K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $170K · Travel and Lodging: $40K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $7,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $169,950.00 |
| Travel and Lodging | $40,194.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,600.00 |
| Food and Beverage | $7,152.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $697,770.59 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Ethicon US, LLC | $2,777.50 | 2021 | |
| Allergan, INC. | $950.93 | 2019-2022 | |
| Baxter Healthcare | $336.80 | 2021-2023 | Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $297.71 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $269.27 | 2020-2025 | Nucala, Trelegy Ellipta |
| Integra Lifesciences Corporation | $240.35 | 2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Conmed Corporation | $225.00 | 2019-2021 | |
| Medtronic, INC. | $172.55 | 2025 | Ligasure, Interstim |
| Becton, Dickinson and Company | $149.99 | 2024 | Hemosphere |
| Vifor Pharma, INC. | $141.34 | 2024 | Zemaira |
| Convatec INC. | $114.56 | 2021 | |
| Gilead Sciences, INC. | $114.52 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $77.53 | 2021-2022 | |
| Astellas Pharma US INC | $64.87 | 2019-2023 | Cresemba |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Liquidia Technologies, INC. | $28.92 | 2025 | Yutrepia |
| Astrazeneca Pharmaceuticals Lp | $27.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.69 | 2020 | |
| Mylan Specialty L.P. | $21.49 | 2024 | Yupelri |
| Mallinckrodt Enterprises LLC | $19.69 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.97 | 2022 | |
| Ani Pharmaceuticals, INC. | $17.06 | 2022 | |
| Inogen, INC. | $15.99 | 2022 | |
| 3b Medical, INC. | $8.92 | 2023 | Luna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.